EA201790626A1 - Макроциклические ингибиторы lrrk2-киназы - Google Patents

Макроциклические ингибиторы lrrk2-киназы

Info

Publication number
EA201790626A1
EA201790626A1 EA201790626A EA201790626A EA201790626A1 EA 201790626 A1 EA201790626 A1 EA 201790626A1 EA 201790626 A EA201790626 A EA 201790626A EA 201790626 A EA201790626 A EA 201790626A EA 201790626 A1 EA201790626 A1 EA 201790626A1
Authority
EA
Eurasian Patent Office
Prior art keywords
kinase
lrrk2
inhibitors
disease
compounds
Prior art date
Application number
EA201790626A
Other languages
English (en)
Other versions
EA032838B1 (ru
Inventor
Ян Хофлак
Петра Блом
Оливье Ляверн
Сильвие Гомес
Original Assignee
Онкодизайн С.А.
Ипсен Фарма С.А.С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Онкодизайн С.А., Ипсен Фарма С.А.С filed Critical Онкодизайн С.А.
Publication of EA201790626A1 publication Critical patent/EA201790626A1/ru
Publication of EA032838B1 publication Critical patent/EA032838B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Настоящее изобретение относится к новым макроциклическим соединениям формулы (I) и композициям, содержащим указанные соединения, действующие в качестве ингибиторов киназы, в частности в качестве ингибиторов LRRK2 (обогащенной лейциновыми повторами киназы 2). Более того, настоящее изобретение предусматривает способы получения раскрытых соединений, а также способы их применения, например, в качестве лекарственного препарата или диагностического средства, в частности для лечения и/или диагностики заболеваний, характеризующихся LRRK2-киназной активностью, таких как расстройств нервной системы, включая болезнь Паркинсона и болезнь Альцгеймера.
EA201790626A 2014-09-17 2015-09-17 Макроциклические ингибиторы lrrk2-киназы EA032838B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14290279 2014-09-17
PCT/EP2015/071349 WO2016042089A1 (en) 2014-09-17 2015-09-17 Macrocyclic lrrk2 kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201790626A1 true EA201790626A1 (ru) 2017-07-31
EA032838B1 EA032838B1 (ru) 2019-07-31

Family

ID=51752058

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790626A EA032838B1 (ru) 2014-09-17 2015-09-17 Макроциклические ингибиторы lrrk2-киназы

Country Status (20)

Country Link
US (1) US10377772B2 (ru)
EP (1) EP3194405B1 (ru)
JP (1) JP2017529365A (ru)
KR (1) KR20170048599A (ru)
CN (1) CN107108641A (ru)
AU (1) AU2015316801B2 (ru)
BR (1) BR112017005299A2 (ru)
CA (1) CA2960777A1 (ru)
DK (1) DK3194405T3 (ru)
EA (1) EA032838B1 (ru)
ES (1) ES2717510T3 (ru)
HU (1) HUE043972T2 (ru)
IL (1) IL251054B (ru)
MX (1) MX2017003470A (ru)
PL (1) PL3194405T4 (ru)
SG (1) SG11201701936WA (ru)
TR (1) TR201904514T4 (ru)
TW (1) TW201625639A (ru)
WO (1) WO2016042089A1 (ru)
ZA (1) ZA201701841B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111221514B (zh) * 2020-01-13 2023-03-03 陕西心像信息科技有限公司 基于OsgEarth的三维可视化组件实现方法及系统
MX2022009285A (es) * 2020-01-31 2022-11-09 Oncodesign Prec Medicine Opm Inhibidores macrocíclicos de la quinasa rip2.
BR112022022511A2 (pt) 2020-05-06 2022-12-13 Servier Lab Inibidores macrocíclicos de lrrk2 quinase
CA3213388A1 (en) 2021-03-18 2022-09-22 Les Laboratoires Servier Macrocyclic lrrk2 kinase inhibitors
WO2023064768A1 (en) * 2021-10-11 2023-04-20 Baylor College Of Medicine G-protein-coupled receptor regulators and methods of use thereof
WO2023073013A1 (en) 2021-10-27 2023-05-04 H. Lundbeck A/S Lrrk2 inhibitors
CN117425660A (zh) * 2022-05-18 2024-01-19 上海翊石医药科技有限公司 一种芳杂环类化合物及其中间体、药物组合物和用途
WO2024056775A1 (en) * 2022-09-15 2024-03-21 H. Lundbeck A/S Macrocyclic leucine-rich repeat kinase 2 (lrrk2) inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
PL175564B1 (pl) 1993-10-01 1999-01-29 Astra Ab Sposób i urządzenie do formowania leku w proszku oraz lek w proszku
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
CZ2005613A3 (cs) 1996-07-24 2017-01-25 Bristol-Myers Squibb Pharma Company Azolopyrimidiny, jejich použití a farmaceutické kompozice na jejich bázi
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
CN1896076A (zh) 2000-12-28 2007-01-17 小野药品工业株式会社 三杂环化合物和包括其作为活性组分的药物
EP1395257A1 (en) * 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
CA2584489C (en) 2004-10-21 2014-07-22 Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders
NO323175B1 (no) 2004-12-23 2007-01-15 Jan O Aasly Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme
FI123725B (fi) 2005-08-01 2013-10-15 Reijo Viljanen Menetelmä sahalaitteen terän jännittämiseksi ja ohjaamiseksi sekä ohjaus- ja jännityslaitteet
KR20080090390A (ko) 2005-11-16 2008-10-08 에스*바이오 피티이 리미티드 헤테로알킬이 결합된 피리미딘 유도체
WO2009127642A2 (en) 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
CA2775753A1 (en) 2009-09-29 2011-04-07 Paula Louise Nichols Lrrk2 kinase inhibitors
SG10201506591TA (en) * 2010-05-20 2015-09-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
HUE029728T2 (en) * 2011-09-30 2017-03-28 Ipsen Pharma Sas Macrocyclic LRRK2 kinase inhibitors
AU2012314376B2 (en) * 2011-09-30 2017-04-06 Oncodesign S.A. Macrocyclic FLT3 kinase inhibitors

Also Published As

Publication number Publication date
PL3194405T3 (pl) 2019-07-31
AU2015316801A1 (en) 2017-04-27
IL251054A0 (en) 2017-04-30
CN107108641A (zh) 2017-08-29
US20170240565A1 (en) 2017-08-24
EA032838B1 (ru) 2019-07-31
PL3194405T4 (pl) 2019-07-31
SG11201701936WA (en) 2017-04-27
CA2960777A1 (en) 2016-03-24
AU2015316801B2 (en) 2019-03-07
EP3194405A1 (en) 2017-07-26
WO2016042089A1 (en) 2016-03-24
TR201904514T4 (tr) 2019-04-22
ES2717510T3 (es) 2019-06-21
IL251054B (en) 2019-03-31
MX2017003470A (es) 2017-08-07
DK3194405T3 (en) 2019-04-15
EP3194405B1 (en) 2018-12-26
HUE043972T2 (hu) 2019-09-30
ZA201701841B (en) 2019-08-28
TW201625639A (zh) 2016-07-16
KR20170048599A (ko) 2017-05-08
JP2017529365A (ja) 2017-10-05
BR112017005299A2 (pt) 2017-12-12
US10377772B2 (en) 2019-08-13

Similar Documents

Publication Publication Date Title
EA201790626A1 (ru) Макроциклические ингибиторы lrrk2-киназы
UA113186C2 (xx) Макроциклічні інгібітори lrrk2 кінази
EA201691514A1 (ru) Соединения
MX2016003582A (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
CO2017004530A2 (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1
EA201270480A1 (ru) Новые соединения
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
EA201391230A1 (ru) Соединения и композиции в качестве ингибиторов trk
BR112014023384A8 (pt) inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos.
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
EA201690520A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
EA201691293A1 (ru) Гетероарильные производные бутановой кислоты в качестве ингибиторов lta4h
EA201791367A1 (ru) Соединения 2,3,4,5-тетрагидропиридин-6-амин и 3,4-дигидро-2h-пиррол-5-амин - ингибиторы бета-секретазы
EA201700042A1 (ru) Соединения имидазопиридазина
EA201591698A1 (ru) Макроциклические ингибиторы киназы lrrk2
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
EA201891710A1 (ru) Терапевтические соединения
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
EA201501175A1 (ru) Новые соединения для лечения злокачественного новообразования
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
CO2018003756A2 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU